Gabather AB (publ)
Gabather AB (publ), a pharmaceutical company, develops drug candidates for the treatment of central nervous system diseases. The company offers drugs primarily in the areas of anti-psychotics, anti-depressants and anxiolytics, and analgesics, as well as cognition-enhancing treatments, including Alzheimer's disease. It focuses on developing GT-002, a pro-cognitive drug candidate for the treatment … Read more
Gabather AB (publ) (GABA) - Net Assets
Latest net assets as of September 2025: Skr-2.61 Million SEK
Based on the latest financial reports, Gabather AB (publ) (GABA) has net assets worth Skr-2.61 Million SEK as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr1.36 Million) and total liabilities (Skr3.98 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr-2.61 Million |
| % of Total Assets | -191.78% |
| Annual Growth Rate | N/A |
| 5-Year Change | -114.47% |
| 10-Year Change | -132.66% |
| Growth Volatility | 304.6 |
Gabather AB (publ) - Net Assets Trend (2014–2024)
This chart illustrates how Gabather AB (publ)'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Gabather AB (publ) (2014–2024)
The table below shows the annual net assets of Gabather AB (publ) from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr-4.17 Million | -959.05% |
| 2023-12-31 | Skr486.00K | -85.86% |
| 2022-12-31 | Skr3.44 Million | -68.64% |
| 2021-12-31 | Skr10.96 Million | -62.00% |
| 2020-12-31 | Skr28.85 Million | -33.82% |
| 2019-12-31 | Skr43.59 Million | +174.71% |
| 2018-12-31 | Skr15.87 Million | -65.32% |
| 2017-12-31 | Skr45.76 Million | +37.89% |
| 2016-12-31 | Skr33.19 Million | +159.56% |
| 2015-12-31 | Skr12.79 Million | +48.06% |
| 2014-12-31 | Skr8.63 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Gabather AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 12338377900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr5.70 Million | % |
| Other Components | Skr115.23 Million | % |
| Total Equity | Skr-4.17 Million | 100.00% |
Gabather AB (publ) Competitors by Market Cap
The table below lists competitors of Gabather AB (publ) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Acutus Medical Inc
NASDAQ:AFIB
|
$732.88K |
|
Altech Advanced Materials AG
XETRA:AMA
|
$732.94K |
|
COGNIZANT TECH SO-A
BE:COZ
|
$733.01K |
|
EuroSite Power Inc
PINK:EUSP
|
$733.07K |
|
Sab Zenzele Kabili Holdings
JSE:SZK
|
$732.71K |
|
Winsome Yarns Limited
NSE:WINSOME
|
$732.62K |
|
Pine Trail Real Estate Investment Trust
V:PINE-UN
|
$731.95K |
|
Sayona Mining Limited
OTCQB:SYAXF
|
$731.37K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Gabather AB (publ)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 486,000 to -4,175,000, a change of -4,661,000 (-959.1%).
- Net loss of 7,753,000 reduced equity.
- Share repurchases of 3,091,000 reduced equity.
- New share issuances of 4,409,000 increased equity.
- Other comprehensive income decreased equity by 818,000.
- Other factors increased equity by 2,592,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-7.75 Million | -185.7% |
| Share Repurchases | Skr3.09 Million | -74.04% |
| Share Issuances | Skr4.41 Million | +105.6% |
| Other Comprehensive Income | Skr-818.00K | -19.59% |
| Other Changes | Skr2.59 Million | +62.08% |
| Total Change | Skr- | -959.05% |
Book Value vs Market Value Analysis
This analysis compares Gabather AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | Skr3.61 | Skr0.06 | x |
| 2015-12-31 | Skr4.29 | Skr0.06 | x |
| 2016-12-31 | Skr9.08 | Skr0.06 | x |
| 2017-12-31 | Skr12.38 | Skr0.06 | x |
| 2018-12-31 | Skr3.08 | Skr0.06 | x |
| 2019-12-31 | Skr6.77 | Skr0.06 | x |
| 2020-12-31 | Skr2.08 | Skr0.06 | x |
| 2021-12-31 | Skr0.82 | Skr0.06 | x |
| 2022-12-31 | Skr0.25 | Skr0.06 | x |
| 2023-12-31 | Skr0.03 | Skr0.06 | x |
| 2024-12-31 | Skr-0.20 | Skr0.06 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Gabather AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-243.80%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -29.95% | 0.00% | 0.00x | 1.06x | Skr-3.45 Million |
| 2015 | -46.65% | 0.00% | 0.00x | 1.06x | Skr-7.24 Million |
| 2016 | -23.79% | -1657.49% | 0.01x | 1.05x | Skr-11.21 Million |
| 2017 | -21.72% | -330.04% | 0.06x | 1.05x | Skr-14.51 Million |
| 2018 | -128.01% | -44218.55% | 0.00x | 1.14x | Skr-21.90 Million |
| 2019 | -32.76% | -3859884.05% | 0.00x | 1.06x | Skr-18.64 Million |
| 2020 | -53.56% | 0.00% | 0.00x | 1.15x | Skr-17.74 Million |
| 2021 | -155.04% | 0.00% | 0.00x | 1.40x | Skr-18.10 Million |
| 2022 | -248.55% | 0.00% | 0.00x | 1.96x | Skr-8.89 Million |
| 2023 | -1941.77% | 0.00% | 0.00x | 15.15x | Skr-9.49 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | Skr-7.34 Million |
Industry Comparison
This section compares Gabather AB (publ)'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $104,251,824
- Average return on equity (ROE) among peers: -45.80%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Gabather AB (publ) (GABA) | Skr-2.61 Million | -29.95% | N/A | $732.74K |
| BioGaia AB (publ) (BIOG-B) | $230.35 Million | 33.15% | 0.21x | $714.80 Million |
| Dicot AB (DICOT) | $73.40 Million | -109.26% | 0.16x | $55.17 Million |
| Enzymatica publ AB (ENZY) | $76.61 Million | -64.91% | 0.64x | $20.94 Million |
| Enorama Pharma AB (ERMA) | $17.02 Million | -96.01% | 1.28x | $566.46K |
| Klaria Pharma Holding AB (KLAR) | $-452.69K | 0.00% | 0.00x | $15.08 Million |
| Moberg Pharma AB (publ) (MOB) | $76.79 Million | -8.31% | 0.20x | $38.42 Million |
| Nanexa AB (NANEXA) | $101.53 Million | -11.22% | 0.36x | $39.92 Million |
| Newbury Pharmaceuticals AB (NEWBRY) | $51.92 Million | -29.67% | 0.75x | $559.69K |
| Orexo AB (ORX) | $311.10 Million | -126.01% | 0.76x | $45.88 Million |